Curcumin Induces MCF-7 Cells Pyroptosis Via Autophagy/CTSB/NLRP3/Caspase-1/GSDMD Signaling Pathway In Vitro And Vivo

Haonan Duan  
Dalian Medical University

Liping Jiang  
Dalian Medical University

Xiance Sun  
Dalian Medical University

Xiaofang Liu  
Dalian Medical University

Guang Yang  
Dalian Medical University

Xianzhi Sun  
Dalian Medical University

Tingting Cheng  
Dalian Medical University

Yuchen Ji  
Dalian Medical University

Fan Zhang  
Dalian Medical University

Yue Du  
Dalian Medical University

Shu Ou  
Dalian Medical University

Rufei Ma  
Dalian Medical University

Xiuliang Guan  
Dalian Medical University

Nan Teng  
Dalian Medical University

Xiaofeng Li (lxf_chen@dmu.edu.cn)  
Dalian Medical University  https://orcid.org/0000-0002-1786-9154
Abstract

Background

Curcumin, as a lipid-lowering drug, has been reported to be effective in the treatment of breast cancer. However, the underlying molecular mechanisms have not been completely investigated.

Methods

MTT assay was used to determine the effect of curcumin on survival rate of MCF-7 cells. The effects of curcumin on tumor growth were observed in animal models of breast cancer. The positive reactions of Caspase-1, IL-1β and IL-18 were detected by immunohistochemistry. LC3, p62, CTSB, ASC, Pro-Caspase-1, GSDMD, NLRP3, Caspase-1, GSDMD-N, IL-1β and IL-18 were determined by Western blot in vitro and vivo. The release of extracellular IL-1β and IL-18 was determined by ELISA. LDH release was measured. The expression level of CTSB in cytoplasm were determined by immunofluorescence assay. Cell proliferation, cell migration and tube formation assays were used to determine the abilities of cells. In this study, NLRP3 inflammasome inhibitor MCC950, cathepsin B inhibitor CA074 Me and autophagy inhibitor 3-MA were used to act on cells to investigate the role of NLRP3 inflammasome, cathepsin B and autophagy in curcumin-induced pyroptosis of MCF-7 breast cancer cells.

Results

In mouse model of breast cancer, we observed that curcumin treatment significantly induced cell autophagy and pyroptosis. In human breast cancer MCF-7 cells, we found that curcumin induced pyroptotic cell death was dependent on the activation of NLRP3/Caspase-1/GSDMD signaling pathway, which was CTSB-dependent. In addition, curcumin-induced cell autophagy caused lysosomal rupture and CTSB release. Furthermore, NLRP3 inhibitor (MCC950) significantly suppressed curcumin-induced pyroptosis, as well as CTSB inhibitor (CA074 Me) and autophagy inhibitor (3-MA). Besides, we also found that curcumin suppressed cell proliferation, cell migration and tube formation, which could be reversed by inhibitors.

Conclusions

In summary, our results demonstrated that curcumin induced MCF-7 cell pyroptosis by the activation of autophagy/CTSB/NLRP3/Caspase-1/GSDMD signaling pathway. These findings offer novel insights into the potential molecular mechanisms of curcumin in treatment of breast cancer.

Introduction
Breast cancer is the most common malignancy in females and ranks second among causes for cancer related death in women \cite{1}. Lifestyle is considered an increasingly significant contributing factor to breast cancer etiology. Obesity, overweight, hypercholesterolemia, metabolic syndrome and alcohol represent risk factors for breast cancer\cite{2}. Chemotherapy has been used as a routine treatment for breast cancer and other cancers. However, chemotherapy is prone to drug resistance and has high side effects. For many years clinicians and researchers have been exploring and examining various therapeutic modalities for breast cancer. Finding natural anticancer compounds with low toxicity and high selectivity has always been the mainstream direction of cancer research.

Curcumin, a lipid-lowering drug is the main component of turmeric, derived from the roots of plant Curcuma longa \cite{3}. It has been widely studied for its anti-cancer, antioxidant, anti-inflammatory, anti-angiogenic and wound healing effects for its medicinal properties in Chinese and Indian systems of medicine\cite{4}. And the main mechanisms of action by which curcumin exhibits its unique anticancer activity include inducing apoptosis and inhibiting tumor proliferation and invasion by suppressing various cellular signaling pathways \cite{5}. Several studies reported that curcumin may regulate multiple signaling pathways, including PI3K/AKT, nuclear factor (NF)-κB, MAPK and JAK/STAT \cite{6}. Recent studies have shown that curcumin can also inhibit the phosphorylation of protein kinase B (Akt)/mammalian target of rapamycin (mTOR), decreased B-cell lymphoma 2 (BCL2) and promoted BCL-2-associated X protein (BAX) and cleavage of caspase 3, subsequently inducing apoptosis of breast cancer cells \cite{7}. However, the mechanism of curcumin in breast cancer has not been totally investigated and lack of in vivo experiments.

Pyroptosis, a proinflammatory form of regulated cell death that depends on the enzymatic activity of inflammatory proteases belong to the caspase family, especially caspase-1\cite{8}. Pyroptosis is generally accompanied by plasma membrane rupture, cytoplasmic swelling, DNA cleavage, NLRP3 inflammasome activation and release of proinflammatory cell contents \cite{9}. Additionally, it needs lipopolysaccharide (LPS) to upregulate,NLRP3 and pro-IL-1β are also essential. Inflammasomes are multi-protein signaling complexes that trigger the activation of inflammatory caspases and the maturation of IL-1β\cite{10}. Nucleotide oligomerization domain-like receptor proteins (NLRPs), especially NLRP3, interact with ASC and pro-caspase-1 to active caspase-1. Caspase-1 is activated within the inflammasome, and active caspase-1 processes gasdermin D (GSDMD) and cytokines such as pro-IL-1β and pro-IL-18. Upon permeabilization of the plasma membrane by GSDMD pores, cells undergo a lytic, pro-inflammatory cell death (pyroptosis) that promotes the release of mature IL-1β and IL-18\cite{11}. Currently, it has been reported that the release of lysosomal cathepsin B induces the activation of NLRP3 inflammasome \cite{12}. Cathepsin B (CTSB) is an intracellular cysteine protease, mainly localized in the lysosome\cite{13}. In addition, the level of CTSB in cytoplasm is related to autophagy flux. When autophagy level increases, autophagic lysosomal degradation leads to cytoplasmic release of CTSB, that related to activation of NLRP3 inflammasomes\cite{14-16}.
Autophagy, a lysosomal dependent catabolism process by eukaryotic cells degraded longevity proteins and their organelles, and is involved in the development, differentiation and homeostasis of cells under various physiological and pathological conditions [17]. Autophagy plays a key role in cancer. In recent years, few studies have indicated that curcumin can induces autophagy [18-20].

In our study, we hypothesized that curcumin might induce autophagy, the cytosolic release of lysosomal contents (CTSB), activation of NLRP3 inflammasome and Caspase-1 and GSDMD-dependent pyroptosis.

Materials And Methods

2.1 Cell culture and treatment

The MCF-7 cells were obtained from the ATCC cell bank. MCF-7 cells were cultured in DMEM medium (Gibco,1853128) supplemented with 10% fetal bovine serum (Biological Industries,1707254) 1% penicillin/streptomycin in a humidified 5% CO2 at 37 °C incubator. Cells were passaged every 3 days at desired confluence. Curcumin was purchased from Sigma Aldrich (CAS No.458-37-7, assay≥94%) and dissolved in DMSO to make a stock solution of 50mM. MCF-7 cells were pretreated with 0.2μg/ml lipopolysaccharide (LPS, Sigma Aldrich, L4391) for 4h and then expose to curcumin (8μM) for 48h. This experiment involved pharmacological inhibitors. MCF-7 cells were pretreated with the addition of autophagy inhibitor 3-methyladenine (3-MA,5mM, Sigma, assay: 98%), CTSB inhibitor CA-074 Me (10μM, AdooQ, A13256, assay>98%), NLRP3 inhibitor MCC950 (5Mm,MCE, HY-12815A, assay>98%) and 0.2μg/ml LPS for 4h, then to expose to curcumin (8μM) for 48h.

2.2 Animal experiment

Ten six-year-old female BALB/c-Nude mice (weight:20g) were purchased from Beijing Vital River, raised in the Institute of Genome Engineered Animal Models for Human Disease of Dalian Medical University (SPF level). The mice were kept under sterile conditions and fed a sterilized mouse diet and water. All mice were anaesthetized via inhalation of isoflurance and a tumor cell suspension of 10⁷ MCF-7 cells in 0.2 ml DMEM was injected subcutaneously into the inguinal of each mouse. When tumors reached about 30-60mm³ at 1 week, the mice were randomly separated into two groups (n = 5/group). The mice were treated with curcumin 200 ug/kg or saline (control) by intraperitoneal injections every day for 4 weeks. Tumor size was measured every week in two perpendicular dimensions with vernier calipers and converted to tumor volume using the formula: a*b*b (a:longer, b:shorter). At the end of the experimental period, all mice were euthanized and tumors were segregated and weighed.

2.3 Cell viability assays

The cytotoxicity of curcumin was measured by using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. MCF-7 cells (5*10⁴/ml) were seeded in 96-well plates and treated with 0,2,4,8,16,32,64,128μM for 24h or 48h. After treatment, MTT (5 mg/ml in sterile PBS, Solarbio, M8180) was added and the 96-well plates were incubated for 4h at 37°C. Thereafter the supernatant was
removed and 100μl DMSO was added into each well for 30 min at 37°C. After that, the plates were shaken carefully until the blue formazan crystals were fully dissolved. Then measured the absorbance at 570 nm using a Bio-Rad Microplate Reader, and the cell viability (%) was calculated using the formula: (A570 of treated group/A570 of control) × 100%.

2.4 Western blot analysis

Proteins were extracted from the MCF-7 cells or from the tumors, completely lysed in the lysis buffer by using a nuclear and cytoplasmic protein extraction kit (Keygen Biotech, China). Then quantified with the BCA Protein Assay kit (Thermo, MK164230). An equal amount (30μg) of total proteins were loaded into different lanes and separated on 10%-15% SDS-Page gel, then blotted and transferred onto polyvinylidene difluoride (PVDF) membranes. Membranes were blocked for 1h with 10% skimmed milk by gentle shaking in a water bath shaker at 37 °C and then incubated with primary antibody LC3 (Abcam, ab192890, 1:1000), p62 (Protein tach, 18420-1-AP, 1:1000), CTSB (Wanleibio, WL01089, 1:500), ASC (Wanleibio, WL02462, 1:500), pro-Caspase-1 (Wanleibio, WL02996,1:500), GSDMD (Cell Signaling Technology, #93709, 1:500), NLRP3 (Wanleibio, WL02635, 1:1000), Caspase-1 (Affinity, AF4005, 1:500), GSDMD-N( Abcam, ab215203), IL-1β (Wanleibio, WL00891, 1:500), IL-18 (Wanleibio, WL01127, 1:1000), β-actin (Cell Signaling Technology, #3700, 1:1000) at 4 ℃ overnight. After washing 3 times with PBS, membranes were incubated with the Secondary Goat anti-mouse IgG and Goat anti-rabbit-IgG at room temperature for 1.5h. The bound antibody was visualized using the Super Signal West Pico Kit (Thermo Scientific) and Bio-Rad ChemiDoc™ MP imaging system (Bio-Rad Laboratories), then analyzed by ImageJ software. The experiments above were independently repeated three times.

2.5 Immunohistochemical assays

The tissue samples of the tumors, preserved in 2.5% glutaraldehyde-polyoxymethylene solution, were dehydrated and embedded in paraffin following routine methods. The paraffin sections were dewaxed and hydrated following routine methods. Rinsed the paraffin sections in PBS-T (3×5 min before each following steps), and then blocked with 3% peroxide-methanol at room temperature for endogenous peroxidase ablation. Afterwards, the sections were immersed in a boiling sodium citrate buffer for 15min, cooled down to room temperature. After that, incubated with blocking buffer (normal goat serum at room temperature for 20 min. Then incubated with primary antibody Caspase1(Affinity, AF4005, 1:100), IL-1β (Wanleibio, WL00891, 1:100), IL-18 (Wanleibio, WL01127, 1:100) at 4°C overnight. After that, the sections were incubated with the Secondary Goat anti-rabbit-IgG at 37°C for 30min. Then incubated with the S-A/HRP at 37°C for 30 min. Colored with 3,3-diaminobenzidin (DAB), and kept at room temperature without light for 10 min. After rinsing adequately with water, the sections were stained with hematoxylin for 5s, then dehydrated and sealed with neutral resins. We observed the sections under an upright microscope.

2.6 Immunofluorescence staining

In order to observe distribution of CTSB in cytoplasm, MCF-7 cells were incubated on slides and treated with primary rabbit monoclonal antibodies against CTSB (Abcam, ab125067, 1:200) after fixation and
blocking. Lysosomes were labeled with Lysotracker Red (Beyotime) and Alexa Fluor 488 secondary antibodies (Proteintech, SA00006-2;1:400) was added in the dark. We analyzed the 4,6-diamidino-2-phenylindole (DAPI) counterstained slides under a fluorescence microscope (40 × 10).

2.7 Lactate dehydrogenase (LDH) release assays

To access the toxic effect of curcumin, the LDH release of MCF-7 cells were measured using an LDH Cytotoxicity Assay Kit (Beyotime, C0016). MCF-7 cells were seeded in 96 well plates to desired confluence and treated with inhibitor for 4h then treated with curcumin for 48h. One hour before the end of the treatment, we added 10% of the LDH release reagent and the original culture volume when the sample showed maximum enzyme activity. The culture supernatants were collected, and the absorbance was read at 490 nm with a microplate reader (Thermo Fisher Scientific). The percentage of LDH released was calculated as the percentage of the total release amount and considered to be the sum of the enzyme activity in the cell lysate and the enzyme activity in the medium.

2.8 Enzyme-linked immunosorbent assays (ELISA)

IL-1β and IL-18 levels were measured by using ELISA kits (Lengton, BPE10083, BPE10092) according to the manufacturer's instructions. MCF-7 cells were seeded in 96-well plates to desired confluence and treated with inhibitor for 4h then treated with curcumin for 48h. The 96-well plates were centrifuged at 3000rpm for 20 min at 4 °C. Finally, the supernatants were collected. A total of 50µl of serially diluted samples and standard were added to the ELISA plate wells and incubated with horseradish peroxidase-conjugated specific antibodies for IL-1β and IL-18 for 60 min at 37 °C. The OD values were detected at 450nm by using microplate reader. The linear regression equation of the standard curve was calculated according to the concentration of the standard corresponding OD value. Finally, the sample concentration was calculated on the linear regression equation according to its OD value.

2.9 Cell migration assays

For the transwell migration assays, MCF-7 cells were treated with various treatments. After indicated treatment, cells were resuspended at serum-free medium then seeded onto the upper chambers with non-coated membrane (24-well insert; 8-mm pore size). After that, we filled the lower chambers with 600ml DMEM containing 10% FBS. After 24 hours of incubation, non-invading cells on the upper surface of the upper chamber were utterly removed by using cotton swabs. Other cells on the lower surface of filters were fixed with methanol for 30 min then stained with 0.1% crystal violet for 30 min. The number of invaded cells was counted under an upright microscope.

2.10 Matrigel tube formation assay

Via a precooled pipette, 50 µL of freeze thawing liquid Matrigel (Corning, 354248, USA) was embedded into a 96-well plate at 4 °C. HUVECs (2 × 10⁴ cells per well) were seeded onto the solidified matrigel 96-well plate and cultured for 12 h at 37°C in 5% CO₂. After the HUVECs were overlaid, we replaced the
culture medium of HUVECs with MCF-7 cell culture medium treated by curcumin and inhibitor. Capillary-like structures were evident and counted using a phase-contrast microscope and the networks formed by HUVECs were quantified with ImageJ.

2.11 Plate clone formation assay

MCF-7 cells were cultured and seeded onto 6-well plates (1000 cells per well) to prepare the cells for the plate clone formation assay. Different wells were treated variously. When the cells in 6-well plates growth to a density of 50% per cluster, which were washed with the phosphate-buffered saline (PBS) and fixed by 4% paraformaldehyde (Sigma-Aldrich, St. Louis, MO, USA). Giemsa stain (Sigma-Aldrich) was used to stain the cells. Eventually, cell clones were counted and analyzed.

2.12 Statistical analysis

All Data were expressed as means ± standard deviation (SD) from at least three independent experiments performed in triplicates and analyzed by using the SPSS 20.0. Significance was determined using one-way analysis of variance (ANOVA) or t-test, and P value < 0.05 was considered statistically significant.

Results

3.1 Curcumin inhibited proliferation and induced cell death in MCF-7 breast cancer cells

In order to assess the effects of curcumin on proliferation and cell death of MCF-7 cells, we performed in vitro assays. As shown in Fig. 1, the cell viability of MCF-7 cells was observed after incubation with different concentrations (0, 1, 2, 4, 8, 16, 32, 64, 128 μM) of curcumin for 48h. At the concentrations above 8 μM, curcumin restrained the growth of MCF-7 cells significantly (P<0.05).

3.2 Curcumin inhibited the tumour growth in mouse model of breast cancer

In vivo assays, we established a mouse model of breast cancer, to comprehend the role of curcumin on tumors’ growth. Results obtained by detection of mice body indicated that curcumin has no toxicity effect on mice. As shown in Fig. 2, tumors’ volumes decreased significantly (P<0.05) after 4 weeks of curcumin treatment as compared with control.

3.3 Curcumin induced pyroptosis in vitro and vivo

To confirm the effect of curcumin in tumor, protein expression levels of LC3, p62, CTSB, ASC, pro-Caspase-1, GSDMD, NLRP3, Caspase-1, GSDMD-N, mature IL-1β and IL-18 were measured. As shown in Fig. 3AB, curcumin treatment (200ug/kg) significantly (P<0.05) decreased the expression of p62 and increased the expression of LC3, CTSB, ASC, pro-Caspase-1, GSDMD, NLRP3, Caspase-1, GSDMD-N, mature IL-1β, mature IL-18 in tumors compared with control. Furthermore, result of immunohistochemical illustrated that tumors treated with curcumin displayed an increase in positive staining of Caspase-1,
mature IL-1β and IL-18 compared with control (Fig. 3CD). In cell experiments (Fig. 4) we found that curcumin treatment (0~128 μM) similarly decreased the expression of p62 and increased the expression of LC3, CTSB, ASC, pro-Caspase-1, GSDMD, NLRP3, Caspase-1, GSDMD-N, mature IL-1β and IL-18 compared with control in LPS-primed cells, with a dose-dependent manner. Notably, there was no significant difference between the LPS group and the control group. Together, these results suggest that curcumin is able to induce pyroptosis in MCF-7 cells and tumors.

3.4 Curcumin-induced MCF-7 pyroptosis depends on activation of the NLRP3 inflammasome

To determine the role of NLRP3 inflammasome components in activation of caspase-1 under curcumin stress, we inhibited the expression of NLRP3 using NLRP3-specific inhibitor MCC950. The MCF-7 cells were pretreated with MCC950 (5 μM) and LPS (1 μg/ml) prior to treatment with 8 μM curcumin for 48 h. Before that, we detected the effect of curcumin on the viability of MCF-7 cells. As shown in Fig. 5AB, NLRP3, Caspase-1, GSDMD-N, mature IL-1β and IL-18 expression were increased by curcumin treatment. However, MCC950 restrained Caspase-1, GSDMD-N expression and IL-1β, IL-18 production. Moreover, MCC950 inhibited the release of mature IL-1β, IL-18 and LDH caused by curcumin (Fig. 5CD). Besides, in functional experiments, MCC950 reversed the amount of MCF-7 cell migration decreased by curcumin treatment (Fig. 5E), as well as the matrigel tube formation (Fig. 5F) and plate clone formation (Fig. 5G). In all, these findings indicated that curcumin-induced pyroptosis is dependent on NLRP3 inflammasome activation.

3.5 Curcumin-induced NLRP3 inflammasome activation and pyroptosis are mediated by cytoplasmic CTSB

It has been indicated that NLRP3 inflammasome activation was associated with a variety of upstream factors, including the release of lysosomal CTSB. As shown, CTSB expression was up-regulated in cells and tumors after curcumin treated. Therefore, we pretreated cells with CA-074 Me, an inhibitor of CTSB, to measure the role of CTSB in curcumin-induced activation of the NLRP3 inflammasome. As shown in Fig. 6AB, the increased expression level of CTSB, NLRP3, Caspase-1, GSDMD-N, mature IL-1β, IL-18 proteins caused by curcumin were inhibited by CA-074 Me compared with control. Besides, CA-074 Me inhibited the release of mature IL-1β, IL-18 and LDH caused by curcumin (Fig. 6CD). Moreover, in functional experiments, CA-074 Me reversed the amount of MCF-7 cell migration decreased by curcumin treatment (Fig. 6E), as well as the matrigel tube formation (Fig. 6F) and plate clone formation (Fig. 6G). As observed by microscopy, immunofluorescence results showed that curcumin treatment could cause MCF-7 intracellular lysosomes to rupture and release CTSB into the cytoplasm, and CA074 Me treatment could significantly reverse this situation (Fig. 6H). Together, the results indicated that curcumin-induced NLRP3 inflammasome activation and cell pyroptosis was CTSB-dependent.

3.6 Curcumin induced up-regulation of MCF-7 autophagy then induced the release of CTSB, the activation of NLRP3 inflammasome and pyroptosis through autophagy
The increase in cytosolic CTSB levels is associated with lysosomal degradation. The results show an increase in autophagic flux in MCF-7 cells. To confirm the change of autophagic flux, we used the autophagy inhibitor 3-MA in MCF-7 cells. As shown in Fig. 7AB, the up-regulation of LC3 and the downregulation of p62 by curcumin were reversed by 3-MA since 3-MA inhibited the fusion of autophagosome and autolysosome. The protein LC3 could be transformed from a soluble form (LC3-I) to a lipidized form (LC3-II) when autophagy was activated. And p62 is a multifunctional protein regulated by the balance between its transcriptional regulation and post-translational autophagic degradation.\textsuperscript{[21]} The LC3 conversion and p62 protein are regard as the most credible biochemical markers of autophagy.\textsuperscript{[22]} These results suggested that curcumin induced up-regulation of MCF-7 autophagy. In addition, the expression of cytosolic CTSB, NLRP3, Caspase-1, GSDMD-N, mature IL-1β, IL-18 were up-regulated by curcumin and down-regulated by 3-MA (Fig. 7AB). Moreover, 3-MA inhibited the release of mature IL-1β, IL-18 and LDH caused by curcumin (Fig. 7CD). Furthermore, in functional experiments, 3-MA reversed the amount of MCF-7 cell migration decreased by curcumin treatment (Fig. 7E), as well as the matrigel tube formation (Fig. 7F) and plate clone formation (Fig. 7G). These results demonstrated that curcumin induced up-regulation of MCF-7 autophagy which was associated with the increase in cytosolic CTSB, activation of NLRP3 inflammasome and pyroptotic cell death.

Discussion

The breast cancer has still been the most common cancer among women worldwide.\textsuperscript{[23]} Recently study indicated that it has a younger trend.\textsuperscript{[24]} Curcumin, a polyphenol extracted from Curcuma longa in 1815, has gained attention from scientists worldwide for its anticancer potential.\textsuperscript{[25]} The phosphoinositide 3-kinase (PI3K)/Akt signaling pathway has always been a focus of interest in breast cancer. However, deregulation of the PI3K/Akt signaling pathway including PIK3CA activating mutation is frequently present in breast cancer.\textsuperscript{[26]} Besides, the mechanism of curcumin in the treatment of breast cancer has not been completely investigated. In the present study, we investigated the effect on pyroptosis in curcumin-treated cells. It is worth mentioning that our study provide the first evidence for curcumin induces cell pyroptosis by activating autophagy/NLRP3/Caspase-1/GSDMD pathway in MCF-7 breast cancer cells. Our study demonstrated that curcumin upregulated the level of autophagy and triggered NLRP3 inflammasome activation, leading to pyroptotic cell death. In addition, curcumin-induced pyroptotic cell death dependent upon the CTSB-mediated activation of NLRP3 inflammasome and curcumin-induced autophagy was implicated in the curcumin-induced release of CTSB.

To date, pyroptosis is a type of programmed cell death mediated by the formation of plasma membrane pores by members of the gasdermin protein family, characterized by the swelling and lysis of cells, and release of many proinflammatory factors.\textsuperscript{[27]} Caspase-1, as a statically determinate proenzyme, is an important component of the inflammasome and is formed by different PRRs through (or without) ASC and Caspase-1 under the stimulation of specific PAMPs and DAMPs.\textsuperscript{[28]} The inflammasome contains an NLR and adaptor protein ASC, which interacts with pro-caspase-1 through caspase recruitment domain, and then self-cleavage forms active caspase-1. Caspase-1 mediated the maturation and secretion of
proinflammatory (IL-1β and IL-18) and lead to pyroptosis[29]. Gasdermin D (GSDMD) is a direct substrate of caspase-1 which can be specially cleaved by inflammatory caspases and plays a key role in the downstream of inflammatory caspases in pyroptosis [30]. Inflammatory caspases cleaved GSDMD to form GSDMD-N, which is capable of forming porelike structures in lipid membranes and thus constitutes the direct and unique effector of pyroptosis [31]. GSDMD-N forms pores in the plasma membrane leading to membrane defects and cytoplasmic protein release [32]. In our study, treatment with curcumin elevated the levels of Caspase-1, GSDMD-N, IL-1β, IL-18 both in vitro and in vivo. Furthermore, the immunohistochemical results of Caspase-1, IL-1β and IL-18 in the tumor tissues of mice were significantly positive compared with control. In addition, the release of IL-1β, IL-18 and LDH in the cytoplasm were also increased. These results demonstrated that curcumin induced Caspase-1 and GSDMD dependent pyroptosis in MCF-7 breast cancer cells.

Inflammation is involved in the development and progression of tumors, as well as in the antitumor response to treatment. Among the inflammasomes family, NLRP3 inflammasome is the most characterized. As we known that NLRP3 is deubiquitinated and associates to ASC, which then associates to procaspase-1 to form a large multimeric polypeptide complex. Pro-caspase-1 undergoes autoproteolytic cleavage, possibly due to proximal-induced multimerization, resulting in the active form of caspase-1 [33]. The activation of NLRP3 inflammasome induces two primary effects, programmed cell death known as pyroptosis, and/or proinflammatory responses caused by the release of inflammatory cytokines IL-1β and IL-18 [34]. Previous studies have found that curcumin induced NLRP3 inflammasome priming and caspase-1 activation [35]. Interestingly, however, few studies have shown that curcumin suppresses IL-1β secretion through Inhibition of the NLRP3 Inflammasome [36]. In our study, we reported that treatment with curcumin elevated the levels of NLRP3, Caspase-1, IL-1β, IL-18, GSDMD and GSDMD-N which was reversed using the NLRP3 inhibitor MCC950 both in vitro and in vivo. These results indicated that curcumin caused activation of the NLRP3 inflammasome and lead to pyroptotic cell death finally.

Previous study confirmed that three signaling pathways of the NLRP3 inflammasome activation involving potassium efflux, generation of reactive oxygen species, and cathepsin B release [37]. Cathepsin B is a cysteine protease involved in the regulation of metalloproteinases, intracellular communication, autophagy induction and immune resistance, and plays an important role in cancer progression and anticancer therapy [38]. Recently study indicated that cathepsin B was required for caspase-1 activation induced by many different NLRP3 inflammasome activators [39]. In our study, the similar results were observed. Treatment with curcumin elevated the levels of CTSB, NLRP3, Caspase-1, GSDMD-N, IL-1β and IL-18 both in vitro and in vivo which could reverse by the cathepsin B inhibitor CA074-Me. Furthermore, the result also showed that CA074 Me reduced cytoplasmic cathepsin B in immunofluorescence assay. Consistent with others [40], these results demonstrated that the activation of the NLRP3 inflammasome was mediated by cathepsin B.

Autophagy is a process by which proteins and organelles are phagocytosed in autophagosomal vesicles and delivered to the lysosome/vacuole for degradation [41]. Autophagy is a tightly coordinated process
that isolates misfolded proteins, damaged or aged organelles, and mutated proteins in double membrane vesicles called autophagosomes that eventually fuse into lysosomes, leading to the degradation of the isolated components \[42\]. During autophagy, cytoplasmic LC3 protein is processed and recruited to the autophagosomal membranes; the autophagosome then fuses with the lysosome to form the autolysosome. Cytoplasmic LC3-I binds to phosphatidylethanolamine to form LC3-II. LC3-II was then incorporated into the autophagosome membrane \[43\]. Ubiquitin-associated protein p62 is a classic autophagy receptor that binds to LC3 and recruits the selected cargo to mature autophagosomes. A lipidated form of LC3, LC3-II, p62 has been shown to be an autophagosomal marker in mammals \[44\]. In our study, treatment with curcumin elevated the levels of LC3, CTSB, NLRP3, Caspase-1, GSDMD-N, IL-1β, IL-18 and decreased the level of p62 both in vitro and in vivo, indicating that the degradation of autophagosomes leads to the release of CTSB into the cytoplasm to activate the NLRP3 inflammasome. Besides, the increased level of CTSB, subsequent activation of NLRP3 inflammasome and Caspase-1 and GSDMD-dependent pyroptotic cell death induced by curcumin were reversed by the autophagy inhibitor 3-MA obviously. These results are consistent with the recent studies \[45][46\]. Notably, curcumin did not increase NLRP3 protein expression after treatment with the autophagy inhibitor 3-MA, suggested that curcumin could not directly induce the activation of NLRP3 inflammasome, which was consistent with the anti-inflammatory properties of curcumin. Taken together, these results demonstrate that curcumin induces autophagy in MCF-7 breast cancer cells and then activates the NLRP3 inflammasome.

In conclusion, our study indicates that curcumin activates the NLRP3 inflammasome by inducing autophagy in MCF-7 breast cancer cells, thus causing pyroptotic cell death via Autophagy/CTSB/NLRP3/Caspase-1/GSDMD signaling pathway. We also demonstrate that the molecular mechanism of NLRP3 inflammasome activation underlies the autophagy and the release of CTSB from autolysosome caused by curcumin treatment. In addition, this study provides a new perspective on curcumin in the treatment of breast cancer. This knowledge may complement the treatment strategy for breast cancer and further confirm the bright future of curcumin in cancer treatment.

**Conclusion**

Curcumin induces MCF-7 breast cancer cells pyroptosis dependent on caspase-1 and GSDMD. Curcumin-induced pyroptotic cell death in MCF-7 breast cancer cells depends on the activation of NLRP3 inflammasome. The activation of NLRP3 inflammasome induces by curcumin is mediated by cytoplasmic CTSB. Curcumin induces autophagy in MCF-7 breast cancer cells, which then induces inflammation and eventually leads to pyroptosis.

**Declarations**

**Ethics approval and consent to participate:** The animal studies covered in this manuscript have been approved by the Ethics Committee of Dalian medical university.

**Consent for publication:** Not applicable
Availability of data and materials: Not applicable

Competing interests: The authors declare that they have no competing interests

Funding: Not applicable

Authors’ contributions: HD was a major contributor in the manuscript. All authors read and approved the final manuscript.

Acknowledgements: Not applicable

Authors' information (optional): Not applicable

References

[1] Fahad Ullah M, Breast Cancer: Current Perspectives on the Disease Status. Adv Exp Med Biol. 2019;1152:51-64.

[2] Garcia-Estevez L, Moreno-Bueno G. Updating the Role of Obesity and Cholesterol in Breast Cancer. Breast Cancer Res. 2019 Mar 1;21(1):35.

[3] Sinha D, Biswas J, Sung B, Aggarwal BB, Bishayee A. Chemopreventive and chemotherapeutic potential of curcumin in breast cancer. Curr Drug Targets. 2012;13:1799–1819.

[4] Xu P, Yao Y, Guo P, Wang T, Yang B, Zhang Z. Curcumin protects rat heart mitochondria against anoxia-reoxygenation induced oxidative injury. Can J Physiol Pharmacol. 2013 Sep;91(9):715-23.

[5] Kunnumakkara AB, Bordoloi D, Padmavathi G, Monisha J, Roy NK, Prasad S, Aggarwal BB. Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. Br J Pharmacol. 2017 Jun;174(11):1325-1348.

[6] Nagaraju GP, Aliya S, Zafar SF, Basha R, Diaz R, El-Rayes BF. The impact of curcumin on breast cancer. Integr Biol (Camb). 2012 Sep;4(9):996-1007.

[7] Hu S, Xu Y, Meng L, Huang L, Sun H. Curcumin inhibits proliferation and promotes apoptosis of breast cancer cells. Exp Ther Med. 2018 Aug;16(2):1266-1272.

[8] Vande Walle L, Lamkanfi M. Pyroptosis. Curr Biol. 2016 Jul 11;26(13):R568-R572.

[9] Man SM, Karki R, Kanneganti TD. Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases. Immunol Rev. 2017 May;277(1):61-75.

[10] Jo EK, Kim JK, Shin DM, Sasakawa C. Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol Immunol. 2016 Mar;13(2):148-59.
[11] Broz P, Pelegrín P, Shao F. The gasdermins, a protein family executing cell death and inflammation. Nat Rev Immunol. 2020 Mar;20(3):143-157.

[12] Wang Y, Jia L, Shen J, Wang Y, Fu Z, Su SA, Cai Z, Wang JA, Xiang M. Cathepsin B aggravates coxsackievirus B3-induced myocarditis through activating the inflammasome and promoting pyroptosis. PLoS Pathog. 2018 Jan 23;14(1):e1006872.

[13] Wu QQ, Xu M, Yuan Y, Li FF, Yang Z, Liu Y, Zhou MQ, Bian ZY, Deng W, Gao L, Li H, Tang QZ. Cathepsin B deficiency attenuates cardiac remodeling in response to pressure overload via TNF-α/ASK1/JNK pathway. Am J Physiol Heart Circ Physiol. 2015 May 1;308(9):H1143-54.

[14] Ozaki E, Campbell M, Doyle SL. Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives. J Inflamm Res. 2015 Jan 16;8:15-27.

[15] Gerónimo-Olvera C, Montiel T, Rincon-Heredia R, Castro-Obregón S, Massieu L. Autophagy fails to prevent glucose deprivation/glucose reintroduction-induced neuronal death due to calpain-mediated lysosomal dysfunction in cortical neurons. Cell Death Dis. 2017 Jun 29;8(6):e2911.

[16] Wang D, Zhang J, Jiang W, Cao Z, Zhao F, Cai T, Aschner M, Luo W. The role of NLRP3-CASP1 in inflammasome-mediated neuroinflammation and autophagy dysfunction in manganese-induced, hippocampal-dependent impairment of learning and memory ability. Autophagy. 2017 May 4;13(5):914-927.

[17] Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science. 2000 Dec 1;290(5497):1717-21.

[18] Lee JE, Yoon SS, Moon EY. Curcumin-Induced Autophagy Augments Its Antitumor Effect against A172 Human Glioblastoma Cells. Biomol Ther (Seoul). 2019 Sep 1;27(5):484-491.

[19] Zhang G, Cao J, Yang E, Liang B, Ding J, Liang J, Xu J. Curcumin improves age-related and surgically induced osteoarthritis by promoting autophagy in mice. Biosci Rep. 2018 Jul 2;38(4):BSR20171691.

[20] Heebkaew N, Rujanapun N, Kunhorm P, Jaroonwitchawan T, Chaicharoenaudomrung N, Promjantuek W, Noisa P. Curcumin Induces Neural Differentiation of Human Pluripotent Embryonal Carcinoma Cells through the Activation of Autophagy. Biomed Res Int. 2019 Jan 21;2019:4378710.

[21] Puissant A, Fenouille N, Auburger P. When autophagy meets cancer through p62/SQSTM1. Am J Cancer Res. 2012;2(4):397-413. Epub 2012 Jun 28.

[22] Jiang P, Mizushima N. LC3- and p62-based biochemical methods for the analysis of autophagy progression in mammalian cells. Methods. 2015 Mar;75:13-8.
[23] Shapira N. The potential contribution of dietary factors to breast cancer prevention. Eur J Cancer Prev. 2017 Sep;26(5):385-395.

[24] Johnson RH, Anders CK, Litton JK, Ruddy KJ, Bleyer A. Breast cancer in adolescents and young adults. Pediatr Blood Cancer. 2018 Dec;65(12):e27397.

[25] Giordano A, Tommonaro G. Curcumin and cancer. Nutrients. 2019 Oct 5;11(10):2376.

[26] Verret B, Cortes J, Bachelot T, Andre F, Amenedos M. Efficacy of PI3K inhibitors in advanced breast cancer. Ann Oncol. 2019 Dec;30 Suppl 10:x12-x20.

[27] Wang Y, Gao W, Shi X, Ding J, Liu W, He H, Wang K, Shao F. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. 2017 Jul 6;547(7661):99-103.

[28] Xia X, Wang X, Cheng Z, Qin W, Lei L, Jiang J, Hu J. The role of pyroptosis in cancer: pro-cancer or pro-"host"? Cell Death Dis. 2019 Sep 9;10(9):650.

[29] Jorgensen I, Miao EA. Pyroptotic cell death defends against intracellular pathogens. Immunol Rev. 2015 May;265(1):130-42.

[30] Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, Zhuang Y, Cai T, Wang F, Shao F. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015 Oct 29;526(7575):660-5.

[31] Gan J, Huang M, Lan G, Liu L, Xu F. High Glucose Induces the Loss of Retinal Pericytes Partly via NLRP3-Caspase-1-GSDMD-Mediated Pyroptosis. Biomed Res Int. 2020 Apr 23;2020:4510628.

[32] Karmakar M, Minns M, Greenberg EN, Diaz-Aponte J, Pestonjamasp K, Johnson JL, Rathkey JK, Abbott DW, Wang K, Shao F, Catz SD, Dubyak GR, Pearlman E. N-GSDMD trafficking to neutrophil organelles facilitates IL-1β release independently of plasma membrane pores and pyroptosis. Nat Commun. 2020 May 5;11(1):2212.

[33] Meyers AK, Zhu X. The NLRP3 Inflammasome: Metabolic Regulation and Contribution to Inflammaging. Cells. 2020 Jul 30;9(8):1808.

[34] Hamarsheh S, Zeiser R. NLRP3 Inflammasome Activation in Cancer: A Double-Edged Sword. Front Immunol. 2020 Jul 8;11:1444.

[35] Miller JM, Thompson JK, MacPherson MB, Beuschel SL, Westbom CM, Sayan M, Shukla A. Curcumin: a double hit on malignant mesothelioma. Cancer Prev Res (Phila). 2014 Mar;7(3):330-40.

[36] Yin H, Guo Q, Li X, Tang T, Li C, Wang H, Sun Y, Feng Q, Ma C, Gao C, Yi F, Peng J. Curcumin Suppresses IL-1β Secretion and Prevents Inflammation through Inhibition of the NLRP3 Inflammasome. J Immunol. 2018 Apr 15;200(8):2835-2846.
[37] Jin C, Flavell RA. Molecular mechanism of NLRP3 inflammasome activation. J Clin Immunol. 2010 Sep;30(5):628-31.

[38] Mijanović O, Branković A, Panin AN, Savchuk S, Timashev P, Ulasov I, Lesniak MS. Cathepsin B: A sellsword of cancer progression. Cancer Lett. 2019 May 1;449:207-214.

[39] Chevriaux A, Pilot T, Derangère V, Simonin H, Martine P, Chalmin F, Ghiringhelli F, Rébé C. Cathepsin B Is Required for NLRP3 Inflammasome Activation in Macrophages, Through NLRP3 Interaction. Front Cell Dev Biol. 2020 Mar 31;8:167.

[40] Jia C, Zhang J, Chen H, Zhuge Y, Chen H, Qian F, Zhou K, Niu C, Wang F, Qiu H, Wang Z, Xiao J, Rong X, Chu M. Endothelial cell pyroptosis plays an important role in Kawasaki disease via HMGB1/RAGE/cathepsin B signaling pathway and NLRP3 inflammasome activation. Cell Death Dis. 2019 Oct 14;10(10):778.

[41] Behrends C, Sowa ME, Gygi SP, Harper JW. Network organization of the human autophagy system. Nature. 2010 Jul 1;466(7302):68-76.

[42] Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer. 2017 Sep;17(9):528-542.

[43] Pugsley HR. Assessing Autophagic Flux by Measuring LC3, p62, and LAMP1 Co-localization Using Multispectral Imaging Flow Cytometry. J Vis Exp. 2017 Jul 21;(125):55637.

[44] Tanida I, Ueno T, Kominami E. LC3 conjugation system in mammalian autophagy. Int J Biochem Cell Biol. 2004 Dec;36(12):2503-18.

[45] Zhang G, Cao J, Yang E, Liang B, Ding J, Liang J, Xu J. Curcumin improves age-related and surgically induced osteoarthritis by promoting autophagy in mice. Biosci Rep. 2018 Jul 2;38(4):BSR20171691.

[46] Lee JE, Yoon SS, Moon EY. Curcumin-Induced Autophagy Augments Its Antitumor Effect against A172 Human Glioblastoma Cells. Biomol Ther (Seoul). 2019 Sep 1;27(5):484-491.